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INTRODUCTION
The incidence of bloodstream infections with fungi (espe-
cially Candida species) has increased substantially during
recent decades (1). One study revealed that the incidence of
candidemia increased from 1.25 episodes per 10,000 patient
days per year in 1999 to 3.06 episodes per 10,000 patient
days per year in 2003 (2). In the United States, Candida spe-
cies are the fourth highest cause of nosocomial bloodstream
infection (3). Moreover, the overall mortality of patients with
a blood culture positive for Candida species ranges from 31%
to 81% (4-11).
Although antifungal agents have recently been developed
and are widely used, the incidence of candidemia and its asso-
ciated mortality are increasing, especially in patients with
severe underlying diseases (12). This trend is associated with
an increase in the number of patients who receive immuno-
suppressive agents after antineoplastic or antirejection chemo-
therapy (13, 14). The known risk factors for candidemia are
immunosuppression, neutropenia, hemodialysis, long-term
use of a central venous catheter, previous broad-spectrum anti-
biotic use, and Candida colonization (1, 13). As these risk
factors are common among intensive-care unit (ICU) pati-
ents, ICUs are high-risk environments for candidemia.
There are few recent studies on the epidemiology of can-
didemia in medical ICUs (MICUs). Therefore, we undertook
a case-control study of MICU patients to evaluate their clin-
ical characteristics, including the incidence of candidemia,
the predominant infectious organisms present, mortality, and
risk factors for candidemia in an MICU.
MATERIALS AND METHODS
Study design and patients
We performed a retrospective 1:3 matched case-control
study. The study was conducted at the Seoul National Univer-
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Clinical Characteristics and Risk Factors for Nosocomial Candidemia
in Medical Intensive Care Units: Experience in a Single Hospital 
in Korea for 6.6 Years
The aim of this study was to determine candidemia incidence among patients in a
medical intensive-care unit (MICU) and the associated mortality rate and to identify
risk factors associated with candidemia. We retrospectively performed a 1:3 matched
case-control study of MICU patients with candidemia. Controls were matched for
sex, age, and Acute Physiology and Chronic Health Evaluation (APACHE) II score.
Candidemia incidence was 9.1 per 1,000 admissions. The most common pathogen
was Candida albicans. Crude mortality was 96% among candidemia patients and
52% among controls (P<0.001). Mortality differed significantly between the groups
according to Kaplan-Meier survival analysis (P=0.024). Multivariate analysis identi-
fied the following independent risk factors for candidemia: central venous catheter-
ization (odds ratio [OR] = 3.2, 95% confidence interval [CI]=1.2-9.0), previous steroid
therapy (OR=4.7, 95% CI=1.8-12.1), blood transfusion during the same admission
period (OR=6.3, 95% CI=2.4-16.7), and hepatic failure upon MICU admission
(OR=6.9, 95% CI=1.7-28.4). In conclusion, we identify an additional independent risk
factor for candidemia, the presence of hepatic failure on MICU admission. Therefore,
increased awareness of risk factors, including hepatic failure, is necessary for the man-
agement of candidemia.
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University Hospital has 5 ICUs: a medical ICU, a surgical
ICU (for patients who underwent abdominal and orthopedic
surgery), an emergency ICU (for patients who presented at the
emergency room), a pediatric ICU (for patients <15 yr old),
and a cardio-pulmonary ICU (for patients who underwent tho-
racic surgery). We studied patients who were admitted to the
MICU. The MICU has 22 beds and admits medical and neu-
rological patients. All patients in the MICU were ≥15 yr
old. The duration of the study was 6 yr and 7 months (1 Jan-
uary 2000 to 31 July 2006).
Definitions
Nosocomial candidemia was defined as one or more blood
cultures positive for Candida species at least 48 hr after admis-
sion. Blood cultures were tested routinely if a patient’s tem-
perature was greater than 38℃. The onset of candidemia was
defined as the date on which the first positive blood culture
was detected. In-hospital mortality was defined as death during
the same period of hospitalization.
Hemodynamic instability was defined as systolic blood
pressure (BP) <90 mmHg, diastolic BP <60 mmHg, mean
arterial BP <70 mmHg, or administration of a vasopressor
on admission to the ICU. Patients were considered as having
neutropenia if their absolute neutrophil count was <500 cells/
mm
3 on admission to the ICU. Acute renal failure was defined
as a 0.5 mg/dL increase in serum creatinine level on admission
to the ICU. Hepatic failure was defined as aspartate amino-
transferase (AST) level >200 IU/L, alanine aminotransferase
(ALT) level >200 IU/L, albumin level <3.0 g/dL, and pro-
thrombin INR >2.0 on admission to the ICU. Central venous
catheters (including internal jugular venous catheters, Hick-
man catheters, Swan-Ganz catheters, or femoral catheters),
nasogastric tubes, and Foley catheters were considered risk
factors for candidemia if they were used for more than 3 days
before the onset of candidemia. Previous total parenteral nutri-
tion (TPN), transfusion with any blood product, including
red blood cells, platelets and fresh, frozen plasma, gastroin-
testinal (GI) bleeding, and steroid therapy were regarded as
risk factors for candidemia when they occurred within 2 weeks
of the onset of candidemia (15). Steroid therapy was defined
as administration of ≥10 mg/day of prednisolone (or the
equivalent dose of an alternative corticosteroid) or adminis-
tration of <10 mg/day of prednisolone or its equivalent for
more than 7 days. The use of immunosuppressive agents was
defined as the administration of chemotherapeutic or anti-
rheumatic agents within 2 weeks of the onset of candidemia
(15). An immunocompromised state was defined as the pres-
ence of a malignancy or the use of immunosuppressive agents
during the same admission. Candida colonization was defined
as a Candida species-positive culture of a sputum, urine, or
fecal sample collected at any time before the onset of candi-
demia.
Matching procedure
Control patients were selected from patients who did not
have candidemia and were admitted to the MICU at about
the same time as the candidemia patients. Control patients
had no evidence of bacterial or fungal growth in blood cultures
at any time during their hospitalization in the MICU. Con-
trol patients were selected according to the following match-
ing criteria: sex, age (±5 yr), and an Acute Physiology and
Chronic Health Evaluation (APACHE) II score (16) of at least
5 on the day of admission to the MICU.
Statistical analysis
Continuous variables are expressed as the mean±standard
deviation or as the median and interquartile range. Patient
characteristics were compared between groups using the Mann-
Whitney test for continuous variables and the chi-square test
for categorical variables. To identify risk factors independent-
ly associated with candidemia, variables that were significant
according to a univariate analysis were subjected to binary
logistic regression analysis. A P value <0.05 was considered
significant. Kaplan-Meier survival curves were compared using
the log-rank test. All statistical analyses were performed using
SPSS software, version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Analysis of patients with candidemia
During the study period, 52 of 5,383 MICU admissions
were identified as having fungemia. Three patients were infect-
ed with species other than Candida (1 patient was positive for
Aspergillus species and 2 patients were positive for Trichosporon
beigelli). Therefore, we analyzed data from 49 patients.
The incidence of candidemia in the MICU was 9.1 per
1,000 admissions. The mean age of the patients was 57.6±
14.1 yr. There were more men than women in the sample
(28:21). Among the candidemia patients, there was no sig-
nificant difference in APACHE II score between the day of
admission to the ICU and the day of onset of candidemia (23.8
±7.7 vs. 23.3±6.4, respectively; P=0.473).
Albicans was the predominant Candida species (32 cases,
65%); non-albicans Candida species accounted for 35% of
infections (13 patients [27%] were infected with C. tropicalis,
3 patients [6%] were infected with C. parapsilosis, and 1 pati-
ent [2%] was infected with C. glabrata). Thirty-five patients
(71%) were treated with an antifungal agent: amphotericin
B was administered to 25 patients and fluconazole was admin-
istered to 10 patients. Eight of the 35 patients were treated
with an antifungal agent before candidemia was diagnosed.
The median duration of antifungal treatment was 11 days
(range, 1-45 days). Bacteremia was present before diagnosis of
672 S.-S. Han, J.-J. Yim, C.-G. Yoo, et al.candidemia in 20 patients (41%). Various causative organisms
of bacteremia were detected: Clostridium perfringens, Escherichia
coli, Enterobacter cloacae, Enterococcus faecium, Klebsiella pneumo-
niae, Staphylococcus aureus, Pseudomonas aeruginosa, and Staphy-
lococcus epidermidis. The median duration of antibiotic use before
the onset of candidemia was 16 days (range, 1-92 days). All
patients were treated with antibiotics before the onset of can-
didemia.
Comparison of candidemia patients with matched control
patients
There were no significant differences in demographic char-
acteristics or underlying diseases between the candidemia
patients and the controls, except for the presence of malig-
nancy (Table 1). Malignancy was more prevalent in patients
with candidemia than in the control patients (P=0.048). This
difference was not associated with solid malignancies (12 can-
didemia patients [25%] vs. 35 control patients [24%]; P=
0.923) but with hematological malignancies (18 candidemia
patients [37%]vs. 31 control patients [21%]; P=0.028). The
dialysis method used for patients with chronic renal failure
did not differ between the 2 groups. Patients with candidemia
had longer stays in hospital and in the MICU compared with
the control group, but there was no difference in their pre-
ICU hospital stays (Table 1). Patients with candidemia were
mechanically ventilated for a longer period during their total
MICU stay than the controls (P=0.001) and had a longer
MICU stay than the controls (P=0.001). At the time of
MICU admission, patients with candidemia were more hemo-
dynamically unstable than the controls (P<0.001).
Univariate analysis identified 8 variables that differed sig-
nificantly between the candidemia patients and the controls
(Table 2). These were central venous catheterization, candida
colonization, an immunocompromised state, previous steroid
therapy, transfusion, TPN, hepatic failure, and neutropenia
on MICU admission. Multivariate analysis of these 8 vari-
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*P<0.05 for candidemia patients vs. controls according to the chi-square
test. 
� P≤0.05 for candidemia patients vs. controls according to the Mann-
Whitney test.
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chron-
ic obstructive pulmonary disease; ICU, intensive-care unit; duration of
pre-ICU stay, general ward stay before ICU admission; duration of pre-
candidemia ICU stay, days from ICU admission to candidemia; delay
in start of therapy, days from diagnosis of candidemia to commence-
ment of antifungal therapy; patients with preemptive therapy, patients
treated with antifungal therapy before candidemia was diagnosed.
Characteristics
Candidemia 
patients (n=49)
Controls
(n=147)
Age (yr), mean±SD 57.6±14.1 57.4±14.0
APACHE II score on admission  23.8±7.7 22.9±7.1
to the ICU, mean±SD
Underlying illness
COPD, No. (%) 0 (0) 5 (3)
Malignancy*, No. (%) 30 (61) 66 (45)
Diabetes, No. (%) 15 (31) 42 (29)
Congestive heart failure, No. (%) 4 (8) 18 (12)
Hypertension, No. (%) 14 (29) 41 (28)
Ischemic heart disease, No. (%) 5 (10) 22 (15)
Cerebral infarct, No. (%) 6 (12) 17 (12)
Chronic renal failure, No. (%) 8 (16) 20 (14)
Chronic liver disease, No. (%) 4 (8) 22 (15)
Transplantation, No. (%) 4 (8) 11 (7)
Adrenal insufficiency, No. (%) 5 (10) 5 (3)
Operation during same 8 (16) 18 (12)
admission, No. (%)
Total duration of hospital stay 38 (2-141) 25 (2-335)
(days)
� , median (range)
Total duration of ICU stay  22 (1-141) 8 (1-119)
(days)
� , median (range)
Duration of pre-ICU stay  8 (0-92) 1 (0-260)
(days), median (range)
Total duration of ventilator use  19 (0-139) 7 (0-119)
(days)
� , median (range)
Duration of precandidemia ICU stay 17 (0-117) -
(days), median (range)
Duration of antifungal therapy  11 (1-45) -
(days), median (range)
Delay in commencement of therapy  2 (0-7) -
(days), median (range) (n=28)
Patients with preemptive  8 (16) -
therapy, No. (%)
Hemodynamic instability on  46 (94) 94 (64)
admission to the ICU
� , No. (%)
Table 1. Baseline characteristics of patients with candidemia
and controls in an MICU
Variables
Candidemia
patients
(n=49)
Controls
(n=147)
OR P * 95% CI
Central venous catheter 42 (86) 67 (46) 6.1 2.7-14.0 <0.001
Nasogastric tube 42 (86) 138 (94) 0.4 0.1-1.1 NS
Foley catheter 46 (94) 145 (82) 0.2 0.1-1.3 NS
Candida colonization 14 (29) 23 (17) 2.2 1.1-4.6 0.045
Immunocompromised state 36 (75) 73 (50) 2.8 1.4-5.7 0.004
Previous steroid therapy 35 (71) 49 (33) 5.0 2.5-10.2 <0.001
Previous GI bleeding 8 (16) 17 (12) 1.5 0.6-3.7 NS
Previous transfusion 40 (82) 50 (34) 8.6 3.9-19.2 <0.001
Previous TPN 11 (23) 7 (5) 5.8 2.1-15.9 <0.001
Hepatic failure on 9 (18) 6 (4) 5.3 1.8-15.7 0.001
admission to the ICU
ARF on admission  24 (49) 51 (35) 1.8 0.9-3.5 NS
to the ICU
Neutropenia on   12 (25) 11 (8) 4.0 1.6-9.8 <0.001
admission to the ICU
Table 2. Results of univariate analysis for candidemia risk factors
Values are expressed as the number (%) of patients. 
*Determined using the chi-squared test.
OR, odds ratio; CI, confidence interval; central venous catheter, internal
jugular venous catheter, Hickman catheter, Swan-Ganz catheter, or fe-
moral catheter; immunocompromised state, malignancy (hematologic
or solid) or use of immunosuppressive agent; GI, gastrointestinal; TPN,
total parenteral nutrition; ARF, acute renal failure; Neutropenia, absolute
neutrophil count <500/μ L.ables using logistic regression revealed that central venous
catheterization, previous steroid therapy, transfusion during
the same admission, and hepatic failure on MICU admission
were independent risk factors for candidemia (Table 3).
In-hospital mortality was 96% (47 of 49 patients) for pati-
ents with candidemia and 52% (77 of 147 patients) for con-
trol patients with odds ratio (OR) 21.4 (95% confidence inter-
val [CI] 5.0-91.2). The significance of this difference in mor-
tality rate was confirmed using Kaplan-Meier survival curves
(P=0.024; Fig. 1).
DISCUSSION
We performed a 1:3 matched case-control study to deter-
mine the incidence of candidemia in MICU patients and the
mortality rate among these patients and to identify factors asso-
ciated with candidemia. We matched cases and controls on
admission using variables known to be strongly correlated with
nosocomial infections and the risk of death (e.g., severe ill-
ness and age). There were no differences between cases and con-
trols in underlying illnesses, except for malignancy. The dura-
tion of the pre-ICU hospital stay did not differ significantly
between groups.
In our study, the incidence of candidemia (9.1 patients per
1,000 admissions) and the crude mortality rate (96%) of can-
didemia patients were greater than those of previous studies,
in which the incidence of candidemia was 0.3-2.5 episodes per
1,000 admissions (4, 7, 12, 17) and the crude mortality rate
was 31-61% (4-9). Lee et al. (18) reported that the incidence of
candidemia in a Korean ICU was 0.3-1.5 episodes per 1,000
patient days and that the crude mortality was 48.3%. This
discrepancy may have arisen because we included patients with
severe disease and only enrolled MICU patients with a pre-
existing risk factor for candidemia. Our study involved more
patients with malignancy (61%) than previous studies (10-
41%) (4, 5, 9, 18), which may also have contributed to the
relatively high incidence of candidemia in our study.
Attributable mortality in our study was 44% (96% minus
52%), which is similar to the results of previous studies (34-
49%). However, crude mortality was higher in our study than
in previous studies (96% vs. 40-61%, respectively) (5, 9, 12,
18, 19). Of 8 patients who received preemptive antifungal
therapy, only 1 survived. There are several potential explana-
tions for the difference in crude mortality between our study
and previous studies. First, criteria for enrollment in our study
were stricter than those of other studies, which enrolled gen-
eral ward patients whose mortality rate was lower than that of
our patients (5, 9, 19). According to previous studies, an
APACHE II score >20 during candidemia is associated with
an elevated mortality rate (12) irrespective of intensive anti-
fungal therapy (15). For this reason, we conducted an APACHE
II score-matched case-control study. This matching procedure
ensures that the control group is valid for comparison of mor-
tality rate. Second, our study included more patients with
malignancy (61%) than previous studies (10-41%) (4, 5, 9,
18). These factors may have been responsible for the high
mortality rate in our study.
The Kaplan-Meier survival analysis showed that the differ-
ence in mortality between the two groups was sustained (P=
0.024). In terms of underlying illness, the candidemia patients
had more malignancies than the control patients (P=0.048).
Therefore, it could be inferred that the difference in the preva-
lence of malignancy contributed to the difference in mortal-
ity. However, survival analysis that excluded patients with a
hematological malignancy showed a consistent result (P=
0.037 according to the log-rank test).
Many studies have been undertaken to evaluate risk fac-
tors for the development of candidemia. However, most stud-
ies were undertaken using specific patient populations or did
not use case-control methodology (4, 10). Using a case-con-
trol design, we identified several independent risk factors
for candidemia in the MICU: central venous catheteriza-
tion, previous steroid therapy, and previous transfusion.
This result is consistent with risk factors identified by other
authors (5, 13, 20, 21).
We identified a new risk factor, viz., the presence of hepatic
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*Determined using binary logistic regression analysis.
OR, odds ratio; CI, confidence interval.
Variables OR 95% CI P *
Central venous catheter 3.2 1.2-9.0 0.023
Previous steroid therapy 4.7 1.86-12.1 0.001
Previous transfusion 6.3 2.4-16.7 <0.001
Hepatic failure on  6.9 1.7-28.4 0.0075
admission to the ICU
Table 3. Results of multivariate logistic regression analysis for can-
didemia risk factors
Fig. 1. Kaplan-Meier survival curves for candidemia patients and
controls in an MICU. The solid line indicates the cumulative sur-
vival of 49 patients with candidemia and the dashed line indi-
cates the cumulative survival of 147 control patients (P=0.024).
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Survival days from ICU admissionfailure on admission to the MICU. A previous study reported
that fungal infection (predominantly candidiasis) is a common
complication (32%) in patients with acute liver failure (22).
However, there are few reports on hepatic failure as an inde-
pendent risk factor for candidemia. In our study, 9 patients
in the candidemia group had hepatic failure on admission to
the MICU. Using multivariate analysis, we identified hepat-
ic failure on admission to the MICU as an independent risk
factor for candidemia (OR, 7.6 ; 95% CI, 1.5-39.0). Hepat-
ic failure may be a risk factor because patients with hepatic
failure have increased susceptibility to infection because of
abnormal immune function (23), increased colonization of
the small bowel (24, 25), impaired phagocytic function (26,
27), or reduced complement levels (28).
Our study has several limitations. First, the incidence of
candidemia in the MICU might have been underestimated.
Because this was a retrospective study, no special fungal blood
cultures were performed. In our hospital, blood is cultured for
5 days using a Bact/Alert 3D instrument (BioMerieux, Inc.,
Durham, NC, USA) when a routine blood culture is request-
ed. If no growth is identified after 5 days, the blood culture
is terminated. However, if a fungal blood culture is request-
ed, the blood is cultured for 3 weeks to identify any slow-grow-
ing Candida species. Several authors have reported that they
cultured blood for more than 5 days to identify specific slow-
growing organisms. Therefore, it has been suggested that the
appropriate duration for blood culture should be determined
on an individual basis according to the clinical relevance of
the culture (29, 30). A prospective study would have avoid-
ed this methodological weakness.
Second, the control patients had no evidence of bacterial or
fungal growth in their blood cultures. However, systemic
bacterial or fungal infections may be present even if blood cul-
tures are negative. In this study, 67 patients (46%) in the con-
trol group used empirical antibiotics. Therefore, the control
group may have included infected patients. However, circum-
vention of this situation is clinically very difficult. Therefore,
we performed a multivariate analysis that included antibiotic
use as a variable.
In conclusion, bloodstream Candida infections in MICUs
are associated with much higher crude mortality rates than
would be expected for uninfected patients with the same dis-
ease severity. We identify an additional independent risk fac-
tor for candidemia, the presence of hepatic failure on MICU
admission. Therefore, increased awareness of risk factors, in-
cluding hepatic failure, is necessary for the management of
candidemia.
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